Creative Commons source reading · Traumatic brain injury recovery
Ectoderm-derived frontal bone mesenchymal stem cells promote traumatic brain injury recovery by alleviating neuroinflammation and glutamate excitotoxicity partially via FGF1.
Qiaozhen Qin; Ting Wang; Zhenhua Xu; Shuirong Liu; Heyang Zhang; Zhangzhen Du; Jianing Wang; Yadi Wang; Zhenning Wang; Shanshan Yuan; Jiamei Wu; Wenyan He; Changzhen Wang; Xinlong Yan; Yan Wang; Xiaoxia Jiang
Originally published in Stem cell research & therapy · 2022-07-26
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background Traumatic brain injury (TBI) leads to cell and tissue impairment, as well as functional deficits. Stem cells promote structural and functional recovery and thus are considered as a promising therapy for various nerve injuries. Here, we aimed to investigate the role of ectoderm-derived frontal bone mesenchymal stem cells (FbMSCs) in promoting cerebral repair and functional recovery in a murine TBI model. Methods A murine TBI model was established by injuring C57BL/6 N mice with moderate-controlled cortical impact to evaluate the extent of brain damage and behavioral deficits. Ectoderm-derived FbMSCs were isolated from the frontal bone and their characteristics were assessed using multiple differentiation assays, flow cytometry and microarray analysis. Brain repairment and functional recovery were analyzed at different days post-injury with or without FbMSC application. Behavioral tests were performed to assess learning and memory improvements. RNA sequencing analysis, immunofluorescence staining, and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) were used to examine inflammation reaction and neural regeneration.
Discussion
In this study, we found that ectoderm-derived FbMSC application in TBI mice significantly inhibited neuroinflammation, promoted neurogenesis, improved cognition and behavioral deficits. Additionally, FGF1 from FbMSCs enhanced glutamate transportation in astrocytes, contributing to the alleviation of glutamate cytotoxicity in neurons (Fig. 8).
Conclusions
In summary, this is the first report on applying ectoderm-derived FbMSCs in a TBI model to alleviate anatomical and functional injury. FbMSCs effectively ameliorated structural and functional injury, markedly reduced neuroinflammation, alleviated excessive glutamate excitotoxicity, and mitigated neuronal damage. Additionally, FGF1 from FbMSCs promoted the transportation of glutamate by astrocytes, mitigating the continuous neuronal loss. Overall, our findings highlight the therapeutic potential of ectoderm-derived FbMSCs for TBI which mostly affect cells from the same embryonic origins as FbMSCs.
Editorial reading guide
- How did the authors define recovery, and when did they measure it?
- Does the outcome reflect a laboratory measure, a functional change or participation in daily life?
